Integrative microarray analysis of pathways dysregulated in metastatic prostate cancer

Cancer Research

Volumn 67, Issue 21, 2007, Pages 10296-10303

  Setlur, Sunita R ^a,b   Royce, Thomas E ^d   Sboner, Andrea ^d   Mosquera, Juan Miguel ^a,b   Demichelis, Francesca ^a,b   Hofer, Matthias D ^a,b   Mertz, Kirsten D ^a,b   Gerstein, Mark ^d,e   Rubin, Mark A ^a,b,c,f,g  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d YALE UNIVERSITY   (United States)

^e Yale University   (United States)

^f BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^g WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEF PROTEIN;

ACCURACY; ALGORITHM; ARTICLE; GENE EXPRESSION PROFILING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; METASTASIS; MICROARRAY ANALYSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE CANCER; VALIDATION STUDY;

GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; NEF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; NEOPLASM METASTASIS; NF-KAPPA B; NF-KAPPA B P50 SUBUNIT; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 35948987161     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-2173     Document Type: Article

References (39)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
2. Dhanasekaran SM, Barrette TR, Ghosh D, et al. Delineation of prognostic biomarkers in prostate cancer. Nature 2001;412:822-6.
3. Beer DG, Kardia SL, Huang CC, et al. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 2002;8:816-24.
4. van 't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530-6.
5. Glinsky GV, Glinskii AB, Stephenson AJ, Hoffman RM, Gerald WL. Gene expression profiling predicts clinical outcome of prostate cancer. J Clin Invest 2004;113:913-23.
6. Rhodes DR, Kalyana-Sundaram S, Mahavisno V, Barrette TR, Ghosh D, Chinnaiyan AM. Mining for regulatory programs in the cancer transcriptome. Nat Genet 2005;37:579-83.
7. Saxena V, Orgill D, Kohane I. Absolute enrichment: gene set enrichment analysis for homeostatic systems. Nucleic Acids Res 2006;34:e151.
8. Segal E, Friedman N, Koller D, Regev A. A module map showing conditional activity of expression modules in cancer. Nat Genet 2004;36:1090-8.
9. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005;102:15545-50.
10. Tomlins SA, Mehra R, Rhodes DR, et al. Integrative molecular concept modeling of prostate cancer progression. Nat Genet 2007;39:41-51.
11. Zeeberg BR, Feng W, Wang G, et al. GoMiner: a resource for biological interpretation of genomic and proteomic data. Genome Biol 2003;4:R28.
12. Goeman JJ, van de Geer SA, de Kort F, van Houwelingen HC. A global test for groups of genes: testing association with a clinical outcome. Bioinformatics 2004;20:93-9.
13. Efron B, Tibshirani R. On testing the significance of sets of genes. Annal Appl Stat 2007;1:107-29.
14. Jiang Z, Gentleman R. Extensions to gene set enrichment. Bioinformatics 2007;23:306-13.
15. Kim SY, Volsky DJ. PAGE: parametric analysis of gene set enrichment. BMC Bioinformatics 2005;6:144.
16. Folks JL. Handbook of statistics v.4: Nonparametric methods. In: Krishnaiah PR and Sen PK, editors. Combination of independent tests. North-Holland, Amsterdam: Elsevier Science Pub. Co.; 1984. p.113-21.
17. Rubin MA, Varambally S, Beroukhim R, et al. Overexpression, amplification, and androgen regulation of TPD52 in prostate cancer. Cancer Res 2004;64:3814-22.
18. Rubin MA, Bismar TA, Andren O, et al. Decreased α-methylacyl CoA racemase expression in localized prostate cancer is associated with an increased rate of biochemical recurrence and cancer-specific death. Cancer Epidemiol Biomarkers Prev 2005;14:1424-32.
19. Perner S, Hofer MD, Kim R, et al. Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. Hum Pathol 2007;38:696-701.
20. LaTulippe E, Satagopan J, Smith A, et al. Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease. Cancer Res 2002;62:4499-506.
21. Lapointe J, Li C, Higgins JP, et al. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci U S A 2004;101:811-6.
22. Suh J, Rabson AB. NF-nB activation in human prostate cancer: important mediator or epiphenomenon? J Cell Biochem 2004;91:100-17.
23. Bismar TA, Demichelis F, Riva A, et al. Defining aggressive prostate cancer using a 12-gene model. Neoplasia 2006;8:59-68.
24. Danielpour D. Functions and regulation of transforming growth factor-β (TGF-β) in the prostate. Eur J Cancer 2005;41:846-57.
25. Slack-Davis JK, Parsons JT. Emerging views of integrin signaling: implications for prostate cancer. J Cell Biochem 2004;91:41-6.
26. Hacker H, Karin M. Regulation and function of IKK and IKK-related kinases. Sci STKE 2006;2006:re13.
27. Varambally S, Yu J, Laxman B, et al. Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell 2005;8:393-406.
28. Shah RB, Mehra R, Chinnaiyan AM, et al. Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res 2004;64:9209-16.
29. Gasparian AV, Yao YJ, Kowalczyk D, et al. The role of IKK in constitutive activation of NF-κB transcription factor in prostate carcinoma cells. J Cell Sci 2002;115:141-51.
30. Palayoor ST, Youmell MY, Calderwood SK, Coleman CN, Price BD. Constitutive activation of IκB kinase a and NF-κB in prostate cancer cells is inhibited by ibuprofen. Oncogene 1999;18:7389-94.
31. Shukla S, MacLennan GT, Fu P, et al. Nuclear factor-κB/p65 (Rel A) is constitutively activated in human prostate adenocarcinoma and correlates with disease progression. Neoplasia 2004;6:390-400.
32. Suh J, Payvandi F, Edelstein LC, et al. Mechanisms of constitutive NF-κB activation in human prostate cancer cells. Prostate 2002;52:183-200.
33. Ismail HA, Lessard L, Mes-Masson AM, Saad F. Expression of NF-κB in prostate cancer lymph node metastases. Prostate 2004;58:308-13.
34. Lessard L, Begin LR, Gleave ME, Mes-Masson AM, Saad F. Nuclear localisation of nuclear factor-κB transcription factors in prostate cancer: an immunohistochemical study. Br J Cancer 2005;93:1019-23.
35. Tergaonkar V, Correa RG, Ikawa M, Verma IM. Distinct roles of IκB proteins in regulating constitutive NF-κB activity. Nat Cell Biol 2005;7:921-3.
36. Lessard L, Karakiewicz PI, Bellon-Gagnon P, et al. Nuclear localization of nuclear factor-κB p65 in primary prostate tumors is highly predictive of pelvic lymph node metastases. Clin Cancer Res 2006;12:5741-5.
37. Domingo-Domenech J, Mellado B, Ferrer B, et al. Activation of nuclear factor-κB in human prostate carcinogenesis and association to biochemical relapse. Br J Cancer 2005;93:1285-94.
38. Lambert PF, Ludford-Menting MJ, Deacon NJ, Kola I, Doherty RR. The NFKB1 promoter is controlled by proteins of the Ets family. Mol Biol Cell 1997;8:313-23.
39. Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005;310:644-8.